218 related articles for article (PubMed ID: 11824879)
1. Trastuzumab: designer drug or fashionable fad?
Freebairn AJ; Last AJ; Illidg TM
Clin Oncol (R Coll Radiol); 2001; 13(6):427-33. PubMed ID: 11824879
[TBL] [Abstract][Full Text] [Related]
2. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
Sakamoto G; Mitsuyama S
Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
[No Abstract] [Full Text] [Related]
3. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu and breast cancer.
Kaptain S; Tan LK; Chen B
Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
[TBL] [Abstract][Full Text] [Related]
5. [Breast cancer].
Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
[TBL] [Abstract][Full Text] [Related]
6. [Use of trastuzumab in the therapy of breast cancer].
Riemer AB; Zielinski CC
Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
[TBL] [Abstract][Full Text] [Related]
7. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
8. Current status of antibody therapy for breast cancer.
Toi M; Takada M; Bando H; Toyama K; Yamashiro H; Horiguchi S; Saji S
Breast Cancer; 2004; 11(1):10-4. PubMed ID: 14718785
[TBL] [Abstract][Full Text] [Related]
9. Her2 and trastuzumab in breast cancer.
Horton J
Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040
[No Abstract] [Full Text] [Related]
10. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
11. Herceptin raises its sights beyond advanced breast cancer.
McNeil C
J Natl Cancer Inst; 1998 Jun; 90(12):882-3. PubMed ID: 9637135
[No Abstract] [Full Text] [Related]
12. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
13. Herceptin: from the bench to the clinic.
Colomer R; Shamon LA; Tsai MS; Lupu R
Cancer Invest; 2001; 19(1):49-56. PubMed ID: 11291556
[No Abstract] [Full Text] [Related]
14. Clinical trials of single-agent trastuzumab (Herceptin).
Baselga J
Semin Oncol; 2000 Oct; 27(5 Suppl 9):20-6. PubMed ID: 11049053
[TBL] [Abstract][Full Text] [Related]
15. Predicting response to herceptin therapy.
Lipton A; Leitzel K; Ali S
Clin Cancer Res; 2004 Mar; 10(5):1559-60. PubMed ID: 15014003
[No Abstract] [Full Text] [Related]
16. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
[TBL] [Abstract][Full Text] [Related]
18. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
19. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and breast cancer: developments and current status.
Tokunaga E; Oki E; Nishida K; Koga T; Egashira A; Morita M; Kakeji Y; Maehara Y
Int J Clin Oncol; 2006 Jun; 11(3):199-208. PubMed ID: 16850126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]